Sab biotherapeutics to present at piper sandler healthcare conference

Sioux falls, s.d., nov. 09, 2023 (globe newswire) -- sab biotherapeutics , inc. (nasdaq: sabs ), (sab), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced that eddie j. sullivan, ph.d., co-founder, president and chief executive officer of sab biotherapeutics will present at the 35th annual piper sandler healthcare conference, taking place from november 28 to november 30, 2023 at the lotte new york palace in new york.
SABS Ratings Summary
SABS Quant Ranking